Home » Stocks » CLSN

Celsion Corporation (CLSN)

Stock Price: $1.17 USD 0.11 (10.38%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $1.18 +0.01 (0.86%) Jul 29, 7:18 PM
Market Cap 91.75M
Revenue (ttm) 500,000
Net Income (ttm) -22.12M
Shares Out 66.30M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $1.17
Previous Close $1.06
Change ($) 0.11
Change (%) 10.38%
Day's Open 1.09
Day's Range 1.07 - 1.25
Day's Volume 5,178,104
52-Week Range 0.43 - 3.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Data show d ose - dependent suppression of immun e- suppressive agents

9 hours ago - GlobeNewsWire

OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted

1 week ago - GlobeNewsWire

These three biotech penny stocks all have developed drugs that have shown strong indications of success. The post 3 Biopharma Penny Stocks That Could be Millionaire Makers appeared first on InvestorPlace.

Other stocks mentioned: VTVT, ZSAN
3 weeks ago - InvestorPlace

LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announc...

4 weeks ago - GlobeNewsWire

Celsion GmbH will manage current and future cancer studies with Thermo D ox ®

1 month ago - GlobeNewsWire

Improvement to the Balance Sheet Leverages Strong Equity Structure

1 month ago - GlobeNewsWire

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Brings extensive biopharmaceutical legal background to the Board

1 month ago - GlobeNewsWire

25-year pharmaceutical industry executive brings broad drug development perspective

1 month ago - GlobeNewsWire

A Quorum Has Been Achieved t o Reconvene Annual Meeting on Thursday June 10, 2021

1 month ago - GlobeNewsWire

Calls for All Shareholders to Vote so Quorum Requirement t o Hold The Meeting is Met

2 months ago - GlobeNewsWire

Focus on Immuno-Oncology and  Next-Generation Vaccines is Suppor ted with a Strong Balance Sheet

2 months ago - GlobeNewsWire

LAWRENCEVILLE, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced ...

2 months ago - GlobeNewsWire

LAWRENCEVILLE, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that...

3 months ago - GlobeNewsWire

Penny stocks are in focus once again as the hype around Doge Coin ramps up The post Top Penny Stocks Today? 3 Cheap Stocks to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | P...

Other stocks mentioned: AMBO, DGLY
3 months ago - PennyStocks

Lawrenceville, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering ...

3 months ago - GlobeNewsWire

Celsion Corporation (NASDAQ: CLSN) has announced a poster highlighting its ongoing Phase 1/2 OVATION 2 Study with GEN-1 in advanced ovarian cancer was presented last week at the Virtual Annual Meeting o...

3 months ago - Benzinga

Company reports further strengthening of R0 resection results in patients treated with GEN-1

3 months ago - GlobeNewsWire

Virtra Inc (NASDAQ: VTSI) shares are trading lower by 22% Wednesday after the company priced a registered direct offering at $6 per share. VirTra is engaged in the sale and development of the judgmental...

Other stocks mentioned: VTSI
3 months ago - Benzinga

LAWRENCEVILLE, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional invest...

3 months ago - GlobeNewsWire

Entered 2021 with a Focus on Cancer Immunotherapy and  Next-Generation Infectious Vaccines and a Strong Balance Sheet

4 months ago - GlobeNewsWire

Wednesday afternoon's and Thursday morning's noteworthy earnings reports were included in our Tuesday preview covering scheduled reports from electric pickup maker Lordstown Motors, cannabis producers S...

Other stocks mentioned: FDX, NKE
4 months ago - 24/7 Wall Street

LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announce...

4 months ago - GlobeNewsWire

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

Other stocks mentioned: AIM, ASXC, IBIO, JAGX, OVID, RIGL, VBIV
4 months ago - InvestorPlace

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

LAWRENCEVILLE, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today an...

4 months ago - GlobeNewsWire

LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today ann...

5 months ago - GlobeNewsWire

Celsion Corporation (NASDAQ: CLSN) reports interim observations and provides an update on its Phase 1/2 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 3/4 ovarian cancer. GEN-1 is a D...

5 months ago - Benzinga

Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement

5 months ago - GlobeNewsWire

Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years

5 months ago - GlobeNewsWire

Celsion (CLSN) stock was on the rise Monday after announcing fast-track approval from the U.S. Food and Drug Administration. The post CLSN Stock: Why Biotech Celsion Is Soaring Today appeared first on I...

5 months ago - InvestorPlace

Celsion's Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases  Granted an Accelerated Development Pathway

5 months ago - GlobeNewsWire

Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2

5 months ago - GlobeNewsWire

Celsion (CLSN) stock is rising higher on Thursday after the release of a letter from chairman, president and CEO Michael Tardugno. The post CLSN Stock: Why Biotech Company Celsion Is Soaring Today appea...

5 months ago - InvestorPlace

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Lawrenceville, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct o...

6 months ago - GlobeNewsWire

LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investo...

6 months ago - GlobeNewsWire

Celsion Corporation (NASDAQ: CLSN) shares are trading at their highest level since early July after the company terminated a stock sale agreement. Celsion revealed in SEC filing it has notified Lincoln ...

6 months ago - Benzinga

Celsion (CLSN) stock is soaring higher Thursday on heavy trading and InvestorPlace has all the details investors need to know. The post CLSN Stock Alert: 5 Things to Know About Celsion as Shares Soar ap...

6 months ago - InvestorPlace

Shares of Celsion Corp. shot up 85.1% toward a six-month high in very active premarket trading Thursday, putting the on track to more than double in two days, after the cancer drug development company d...

6 months ago - Market Watch

LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Celsion Corporation.

7 months ago - Business Wire

LOS ANGELES, Dec. 28, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation ("Celsion" or "t...

7 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - December 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November ...

7 months ago - Newsfile Corp

NEW YORK, Dec. 26, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015...

7 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November ...

7 months ago - Newsfile Corp

NEW YORK, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from...

7 months ago - GlobeNewsWire

NEW YORK, Dec. 22, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10...

7 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - December 15, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November...

7 months ago - Newsfile Corp

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from...

7 months ago - GlobeNewsWire

About CLSN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and i... [Read more...]

Industry
Biotechnology
IPO Date
Mar 5, 1985
CEO
Michael Tardugno
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
CLSN
Full Company Profile

Financial Performance

In 2020, Celsion's revenue was $500,000, a change of 0.00% compared to the previous year's $500,000. Losses were -$21.48 million, 27.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Celsion stock is "Strong Buy" and the 12-month stock price forecast is 4.00.

Price Target
$4.00
Analyst Consensus: Strong Buy